Biocon recalls over 3000 bottles of antifungal drug Posaconazole Delayed Release in US

Published On 2023-02-19 05:45 GMT   |   Update On 2023-10-26 06:46 GMT
Advertisement

New Delhi: Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).

In its latest Enforcement Report, the US health regulator said that the Bengaluru-based firm is recalling 3,665 bottles of Posaconazole Delayed-Release Tablets (100 mg, 60-count bottle), used to treat serious fungal infections like invasive aspergillosis.

Advertisement

USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to “Failed Impurities/Degradation Specifications: High Out Of Specification degradation results.” The lot has been manufactured by Biocon Pharma and distributed in the US by Iselin-based Biocon Pharma Inc, it added.

Biocon initiated the Class II nationwide (US) recall on January 31, this year.

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

On February 12, Biocon stated that the USFDA has issued a Complete Response Letter (CRL) for the biologics licence application filed for Bevacizumab by its partner Viatris.

The USFDA issues a CRL to convey to a company that its initial review of an application is complete and it cannot approve the application in its present form.

Read also: Biocon partner Viatris gets Complete Response Letter from USFDA for Bevacizumab license application

Earlier on January 7, the company had stated that the USFDA has issued a complete response letter for Biocon Biologics' application for Insulin-R, a proposed biosimilar for diabetes treatment.

Read also: Biocon Biologics gets complete response letter from USFDA for proposed biosimilar Insulin-R

Based in Bangalore, Biocon Limited is an Indian biopharmaceutical company. It was founded by Kiran Mazumdar-Shaw in 1978. The company's formulations for the Indian market include oncology, immunotherapy, metabolics and nephrology products.


Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News